-+ 0.00%
-+ 0.00%
-+ 0.00%

Pharvaris to present Phase 3 RAPIDe-3 end-of-progression data for oral deucrictibant in hereditary angioedema at EAACI 2026

PUBT·05/29/2026 10:51:01
Listen to the news
Pharvaris to present Phase 3 RAPIDe-3 end-of-progression data for oral deucrictibant in hereditary angioedema at EAACI 2026
  • Pharvaris flagged new Phase 3 RAPIDe-3 end-of-progression results for oral deucrictibant in on-demand hereditary angioedema attacks.
  • Data will be presented at the EAACI Annual Congress 2026 in Istanbul on June 12-15, 2026.
  • Additional EAACI presentations will cover cardiovascular safety, long-term prophylaxis experience, and a biomarker assay to distinguish angioedema types.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605290650PRIMZONEFULLFEED9728307) on May 29, 2026, and is solely responsible for the information contained therein.